Replies to post #78610 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

I mentioned the following reason before. Daptomycin will go off patent in 2016. Since the earliest Brilacidin can be approved is 2016, B will not affect D in sales before then. If the trial was Phase 3 and B will be approved in 2015, Cubist's stock price will definitely be affected IMO.